6533b7dcfe1ef96bd1273529

RESEARCH PRODUCT

Increased cerebrospinal fluid albumin and immunoglobulin A fractions forecast cortical atrophy and longitudinal functional deterioration in relapsing-remitting multiple sclerosis.

Felix LuessiMuthuraman MuthuramanJulia KrothGabriel Gonzalez-escamillaVinzenz FleischerJulia KrämerFrauke ZippSergiu GroppaStefan BittnerSven G. MeuthNabin KoiralaDumitru Ciolac

subject

Immunoglobulin AAdultMalePathologymedicine.medical_specialty03 medical and health sciencesYoung Adult0302 clinical medicineCerebrospinal fluidMultiple Sclerosis Relapsing-RemittingAlbuminsmedicineHumansIn patient030212 general & internal medicineLongitudinal StudiesCortical atrophyCerebral Cortexbiologybusiness.industryMultiple sclerosisAlbuminmedicine.diseasePrognosisImmunoglobulin ADisease evolutionNeurologyRelapsing remittingbiology.proteinFemaleNeurology (clinical)Atrophybusiness030217 neurology & neurosurgeryBiomarkers

description

Background: Currently, no unequivocal predictors of disease evolution exist in patients with multiple sclerosis (MS). Cortical atrophy measurements are, however, closely associated with cumulative disability. Objective: Here, we aim to forecast longitudinal magnetic resonance imaging (MRI)-driven cortical atrophy and clinical disability from cerebrospinal fluid (CSF) markers. Methods: We analyzed CSF fractions of albumin and immunoglobulins (Ig) A, G, and M and their CSF to serum quotients. Results: Widespread atrophy was highly associated with increased baseline CSF concentrations and quotients of albumin and IgA. Patients with increased CSFIgA and CSFIgM showed higher functional disability at follow-up. Conclusion: CSF markers of blood–brain barrier integrity and specific immune response forecast emerging gray matter pathology and disease progression in MS.

yearjournalcountryeditionlanguage
2017-12-11Multiple sclerosis (Houndmills, Basingstoke, England)
10.1177/1352458517748474https://pubmed.ncbi.nlm.nih.gov/29226779